| Brain | Adjuvant | RTOG 0525: Phase III Trial Comparing Conventional Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma | Details |
| Breast | | CTSU/ECOG PACCT-1: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment TAILORx Trial | Details |
| Breast | | MHUMC/WUMC: Identification Of Novel Genetic Factors That Contribute To Risk For Breast Cancer | Details |
| Breast | Adjuvant | 2006.01.02: Differentiation and Consolidation: Adjuvant Breast Cancer Therapy Decisions | Details |
| Breast | Adjuvant | CTSU IBCSG 24-02: A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer | Details |
| Breast | Adjuvant | MHUMC 2006.01.02: Differentiation and Consolidation: Adjuvant Breast Cancer Therapy Decisions | Details |
| Breast | Adjuvant | NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin, and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients With Node-Negative Breast Cancer | Details |
| Breast | Adjuvant | SWOG S0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer | Details |
| Breast | Adjuvant, Stage II | NSABP B-38: A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by Dose-Dense (DD) Paclitaxel (DDAC?P); Dose-Dense Doxorubicin/Cyclophosphamide Followed by Dose-Dense Paclitaxel Plus Gemcitabine (DD AC?PG) | Details |
| Breast | Advanced/Metastatic | SWOG S0511: A Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients with Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer | Details |
| Breast | Behavioral | 2005.12.05: Awareness and Attitudes in Southeast Georgia Concerning BRCA Testing | Details |
| Breast | Cancer Control | MHUMC 2005.05.09: Identification Of Novel Genetic Factors That Contribute To Risk For Breast Cancer | Details |
| Breast | Metastatic | SWOG S0430: Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients With Metastatic Breast Cancer | Details |
| Breast | Neoadjuvant | ACOSOG Z1031: A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with clinical Stage II and III Estrogen Receptor Positive Breast Cancer | Details |
| Breast | Stage 0, I, II | NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | Details |
| Breast | Stage 0, I, II, III | CALGB 40101: Cyclophosphamide And Doxorubicin (CA) (4 Versus 6 Cycles) Versus Paclitaxel (12 Weeks Versus 18 Weeks) As Adjuvant Therapy For Women With Node-Negative Breast: A 2x2 Factorial Phase III Randomized Study | Details |
| Breast | Stage 0, I, II, III | RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer | Details |
| Cancer Control | | SNX-1012-CLN2-006: A Phase II, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the duration and severity of Ulcerative Oral Mucositis in patients Receiving Cytotoxic Chemotherapy for Colorectal or Breast Cancer | Details |
| Cancer Control | | UMCC 0003: Protemics Biomarker Development Laboratory | Details |
| Cancer Control | | URCC U1902: A Phase II/III Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Ginger (Zingiber Officinale) for Nausea Caused by Chemotherapy for Cancer | Details |
| Cancer Control | | URCC U2901: Phase III Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Modafinil on Fatigue in Cancer Patients Receiving Chemotherapy | Details |
| Colorectal | | CALGB 80402: Phase II Trial of LE-SN38 in Patients with Metastatic Colorectal Cancer After Progression on Oxaliplatin | Details |
| Colorectal | | CTSU E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab, in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers | Details |
| Colorectal | | CTSU E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin versus Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation | Details |
| Colorectal | | CTSU NCCTG N0147: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer | Details |
| Colorectal | | NSABP C-10: A Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy Plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronus Asymptomatic Primary Tumor | Details |
| Colorectal | | NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum | Details |
| Colorectal | | RTOG 0247: Randomized Phase II Trial of Neoadjuvant Combined Modality Therapy for Locally Advanced Rectal Cancer (T3-4M0; Radiation Therapy) (No IMRT Allowed) | Details |
| Colorectal | Advanced/Metastatic | CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum | Details |
| Colorectal | Neoadjuvant | ACOSOG Z6041: A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer | Details |
| Genitourinary | | 2006.01.01: EDAP Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU) Indicated for Treatment of Low Risk, Localized Prostate Cancer | Details |
| Genitourinary | | 2006.02.04: A Longitudinal Study of Quality of Life for Prostate Cancer Patients | Details |
| Genitourinary | | CALGB 90401: A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone With and Without Bevacizumab in Men with Hormone Refractory Prostate Cancer | Details |
| Genitourinary | | RTOG 0521: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer | Details |
| Genitourinary | | SWOG S0306: Phase II Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium (Progression or recurrent; T2-4N0-3M1 [or N + M0 unresectable) | Details |
| Gynecologic | Ancillary | GOG 136: Acquisition of Human Gynecologic Specimens and Serum To Be Used in Studying the Causes, Diagnosis, Prevention, and Treatment of Cancer | Details |
| Gynecologic | Cervical | GOG 204: A Randomized Phase III Trial of Paclitaxel plus Cisplatin versus Vinorelbine plus Cisplatin versus Gemcitabine plus Cisplatin versus Topotecan plus Cisplatin in Stage IV-B, Recurrent or Persistent Carcinoma of the Cervix | Details |
| Gynecologic | Cervical | GOG 206: Lymphatic Mapping And Sentinel Node identification In Patients In Stage IB Cervical Carcinoma | Details |
| Gynecologic | Cervical | GOG 227: Phase II Evaluation of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix Group A | Details |
| Gynecologic | Endometrial | GOG 129-P: A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Endometrial Carcinoma | Details |
| Gynecologic | Endometrial | GOG 181B: A Phase II Evaluation of Trastuzumab (MoAB HER2) in Patients with Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy | Details |
| Gynecologic | Endometrial | GOG 188: Phase II Study Of Faslodex In Recurrent/Metastatic Endometrial Carcinoma | Details |
| Gynecologic | Endometrial | GOG 209: Randomized Phase III Trial Of Doxorubicin/Cisplatin And G-CSF Versus Carboplatin/Paclitaxel In Patients With Stage III And IV Or Recurrent Endometrial Cancer | Details |
| Gynecologic | Endometrial | GOG 210: A Molecular Staging Study of Endometrial Carcinoma | Details |
| Gynecologic | Other | GOG 174: A Randomized Trial Of Weekly Parental Methotrexate Versus “Pulsed” Dactinomycin As Primary Management For Low Risk Gestational Trophoblastic Neoplasia | Details |
| Gynecologic | Other | GOG 192: A Randomized Phase III Trial Of Amifostine Versus No Treatment For Platinum Induced Peripheral Neuropathy | Details |
| Gynecologic | Ovarian | GOG 175: A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients with Early Stage Ovarian Carcinoma | Details |
| Gynecologic | Ovarian | GOG 190: An Exploratory Evaluation Of Fenretinide (4-HPR) As A Chemoprevention Agent For Ovarian Carcinoma | Details |
| Gynecologic | Ovarian | GOG 198: A Randomized Study of Tamoxifen Versus Thalidomide In Patienst With Biochemical Recurrence Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma After First Line Chemotherapy | Details |
| Gynecologic | Ovarian | GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or primary Peritoneal Cancer Who Achieve A Complete Clinical Response to primary Platinum/Taxane Chemotherapy | Details |
| Gynecologic | Ovarian | GOG 218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed Previously Untreated Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer | Details |
| Gynecologic | Pharmaceutical/Industry | B9EUS-S302: Phase III Randomized Trial Of Induction Chemotherapy With Gemcitabine And Carboplatin Versus Paclitaxel And Carboplatin Followed By Paclitaxel Consolidation In Patients With Advanced Primary Epithelial Ovarian Or primary Peritoneal Cancer | Details |
| Gynecologic | Pharmaceutical/Industry | SK & F-104864/902: An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 And 8 Every 21 Days) As Second-Line Therapy In Subjects With Potentially Platinum-Sensitive Relapsed Ovarian Cancer | Details |
| Gynecologic | Pharmaceutical/Industry | TLK286.3024 (Assist-3): Phase 3 Randomized Study of TLK286 (Telcyta) In Combination With Carboplatin Versus Liposomal Doxorubicin As A Second-Line Therapy In Platinum Refractory Or Resistant Ovarian Cancer | Details |
| Gynecologic | Preventative | GOG 199: A Prospective Study Of Risk-Reducing Salpingo-Oophorectomy And Longitudinal CA-125 Screening Among Women At Increased Genetic Risk Of Ovarian Cancer | Details |
| Gynecologic | Uterine | GOG 230B: A Phase II Evaluation of Thalidomide in the Treatment of Recurrent or Persistent Carcinoma of the Uterus | Details |
| Gynecologic | Vulva | GOG 173: Intraoperative Lymphatic Mapping In Patients With Stage I And II Squamous Carcinoma Of The Vulva | Details |
| Gynecologic | Vulva | GOG 205: A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva | Details |
| Lung | Correlatives | SWOG S9925: Lung Cancer Specimen Repository Protocol (Specimen Repository Companion) | Details |
| Lung | Correlatives | Title | Details |
| Lung | Extensive | SWOG S0124: Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer (E-SCLC) | Details |
| Lung | Extensive | SWOG S0435: A Phase II Trial of BAY 43-9006 in patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer | Details |
| Lung | Industry | OSI3364g: A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for treatment of Advanced Non-small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy | Details |
| Lung | Mesothelioma | SWOG S0509: A Phase II study of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma | Details |
| Lung | Stage IB, II, IIIA | CTSU E3598: A Phase III Trial of Carboplatin, Paclitaxel and Throacic Radiotherapy, With or Without Thalidomide, in Patients with Stage III Non-Small Lung Cancer (Stages IIIA [unresectable] and IIIB, radiation therapy) | Details |
| Lung | Stage IB, II, IIIA | CALGB 30406: A Phase II Randomized Study of OSI-774 (Erlotinib) with or without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers | Details |
| Lung | Stage IB, II, IIIA | CALGB 30407: A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin with or without Cetuximab in Stage III Non-Small Cell Lung Cancer | Details |
| Lung | Stage IB, II, IIIA | SWOG S0424: Molecular Epidemiology Case- Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men | Details |
| Lung | Stage IB, II, IIIA | SWOG S0429: A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer | Details |